Patent · US Expired

Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury

US6465464B2 · kind B2 · utility

41Cited by
4References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 22, 2002
Grant dateOct 15, 2002
Priority date
Expiry dateFeb 22, 2022

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a method of providing neuroprotection to a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action on its nerve cells an effective amount of a compound of formula I to inhibit or prevent nerve cell injury or death wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2- or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof. Such noxious action may result from ischemia, e.g. spinal ischemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.